Advances in targeted therapies VI
F C Breedveld, J R Kalden, and J S Smolen
Ann Rheum Dis 2004; 63 (Supplement 2
): ii1. doi:10.1136/ard.2004.028779
[Extract]
[Full text]
[PDF]
[Request Permissions]
Updated consensus statement on biological agents, specifically tumour necrosis factor (TNF ) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, and P J Mease
Ann Rheum Dis 2004; 63 (Supplement 2
): ii2-ii12. doi:10.1136/ard.2004.029272
[Extract]
[Full text]
[PDF]
[Request Permissions]
Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues
F Wolfe, K Michaud, and E M DeWitt
Ann Rheum Dis 2004; 63 (Supplement 2
): ii13-ii17. doi:10.1136/ard.2004.028530
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection
L H Calabrese, N Zein, and D Vassilopoulos
Ann Rheum Dis 2004; 63 (Supplement 2
): ii18-ii24. doi:10.1136/ard.2004.028209
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Pharmacogenetics in the rheumatic diseases
B N Cronstein
Ann Rheum Dis 2004; 63 (Supplement 2
): ii25-ii27. doi:10.1136/ard.2004.028217
[Extract]
[Full text]
[PDF]
[Request Permissions]
What precedes development of rheumatoid arthritis?
L Klareskog, L Alfredsson, S Rantapää-Dahlqvist, E Berglin, P Stolt, and L Padyukov
Ann Rheum Dis 2004; 63 (Supplement 2
): ii28-ii31. doi:10.1136/ard.2004.028225
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?
T Pincus and T Sokka
Ann Rheum Dis 2004; 63 (Supplement 2
): ii32-ii39. doi:10.1136/ard.2004.028415
[Abstract]
[Full text]
[PDF]
[Request Permissions]
The International Classification of Functioning, Disability and Health (ICF) Core Sets for rheumatoid arthritis: a way to specify functioning
G Stucki and A Cieza
Ann Rheum Dis 2004; 63 (Supplement 2
): ii40-ii45. doi:10.1136/ard.2004.028233
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Should infection still be considered as the most likely triggering factor for rheumatoid arthritis?
S M Carty, N Snowden, and A J Silman
Ann Rheum Dis 2004; 63 (Supplement 2
): ii46-ii49. doi:10.1136/ard.2004.028241
[Extract]
[Full text]
[PDF]
[Request Permissions]
New issues in tuberculosis
S H E Kaufmann
Ann Rheum Dis 2004; 63 (Supplement 2
): ii50-ii56. doi:10.1136/ard.2004.028258
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Nuclear factor (NF)- B proteins: therapeutic targets
I M Verma
Ann Rheum Dis 2004; 63 (Supplement 2
): ii57-ii61. doi:10.1136/ard.2004.028266
[Extract]
[Full text]
[PDF]
[Request Permissions]
Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs
M Karin
Ann Rheum Dis 2004; 63 (Supplement 2
): ii62-ii64. doi:10.1136/ard.2004.028274
[Abstract]
[Full text]
[PDF]
[Request Permissions]
B cell signalling as therapeutic target
R H Carter
Ann Rheum Dis 2004; 63 (Supplement 2
): ii65-ii66. doi:10.1136/ard.2004.028282
[Extract]
[Full text]
[PDF]
[Request Permissions]
Targeting the Jak/STAT pathway for immunosuppression
J J OShea
Ann Rheum Dis 2004; 63 (Supplement 2
): ii67-ii71. doi:10.1136/ard.2004.028290
[Extract]
[Full text]
[PDF]
[Request Permissions]
DREAMing about arthritic pain
H-Y M Cheng and J M Penninger
Ann Rheum Dis 2004; 63 (Supplement 2
): ii72-ii75. doi:10.1136/ard.2004.029942
[Abstract]
[Full text]
[PDF]
[Request Permissions]
A toll for T cell costimulation
F Y Liew, M Komai-Koma, and D Xu
Ann Rheum Dis 2004; 63 (Supplement 2
): ii76-ii78. doi:10.1136/ard.2004.028308
[Extract]
[Full text]
[PDF]
[Request Permissions]
The utility of tumour necrosis factor blockade in orphan diseases
E C Keystone
Ann Rheum Dis 2004; 63 (Supplement 2
): ii79-ii83. doi:10.1136/ard.2004.028498
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Chemokines: role in inflammation and immune surveillance
B Moser and K Willimann
Ann Rheum Dis 2004; 63 (Supplement 2
): ii84-ii89. doi:10.1136/ard.2004.028316
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Toll-like receptors in rheumatoid arthritis joint destruction mediated by two distinct pathways
C Ospelt, D Kyburz, M Pierer, R Seibl, M Kurowska, O Distler, M Neidhart, U Muller-Ladner, T Pap, R E Gay, and S Gay
Ann Rheum Dis 2004; 63 (Supplement 2
): ii90-ii91. doi:10.1136/ard.2004.028324
[Extract]
[Full text]
[PDF]
[Request Permissions]
Defining a role for fibroblasts in the persistence of chronic inflammatory joint disease
C D Buckley, A Filer, O Haworth, G Parsonage, and M Salmon
Ann Rheum Dis 2004; 63 (Supplement 2
): ii92-ii95. doi:10.1136/ard.2004.028332
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Cell therapy for autoimmune diseases: does it have a future?
A Radbruch and A Thiel
Ann Rheum Dis 2004; 63 (Supplement 2
): ii96-ii101. doi:10.1136/ard.2004.028340
[Abstract]
[Full text]
[PDF]
[Request Permissions]